Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 6:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 6,454 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Kidney Clear all

Conditions: Chronic Kidney Disease
Interventions: Aerobic exercise training, Health Education; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 60 Years to 85 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: Renal Impairment
Interventions: Tavapadon; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Jacksonville, Florida • Miami, Florida • Tampa, Florida

Conditions: Kidney Disease, Albuminuria
Interventions: 6R BH4, Vitamin C; Drug · Dietary Supplement
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
Interventions: Elinzanetant (BAY3427080); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Crohn's Disease, Nephrotic Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 5 Years to 21 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Renal Impairment
Interventions: TR-701 FA single infusion, TR-701 FA; Drug
Lead sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Orlando, Florida • Minneapolis, Minnesota

Conditions: Multicystic Dysplastic Kidney, Polycystic Kidney Disease, Fetal Renal Anomaly, Anhydramnios, Potter Syndrome, Lung Hypoplasia, Multicystic Renal Dysplasia, Bilateral, Lower Urinary Tract Obstructive Syndrome, Bilateral Renal Agenesis
Interventions: Amnioinfusion; Other
Lead sponsor: Fetal Care Center, PLLC; Industry
Eligibility: Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Renal Cell Carcinoma
Interventions: Nivolumab, Axitinib, Cabozantinib; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 8
States / cities: Springdale, Arkansas • Louisville, Kentucky • St Louis, Missouri + 5 more

Conditions: Pyelonephritis
Interventions: No intervention; Other
Lead sponsor: Olive View-UCLA Education & Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Sylmar, California

Conditions: Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Squamous Cell Carcinoma of the Bladder, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Interventions: trastuzumab, paclitaxel, carboplatin, gemcitabine hydrochloride, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hemorrhagic Fever With Renal Syndrome
Interventions: Vaccine/device combination for prevention of HFRS; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 49 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Kidney Transplant
Interventions: Alemtuzumab; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic
Interventions: Selenomethionine (SLM), Axitinib, Pembrolizumab; Drug
Lead sponsor: Fernando Maciel Barbosa; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions: bortezomib, gemcitabine hydrochloride; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 70 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Kidney Cancer
Interventions: NeoVax, Ipilimumab; Drug
Lead sponsor: Patrick Ott, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Physical Disability
Interventions: Virtually supervised exercise, Health education; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Chronic Kidney Disease
Interventions: Rifaximin, Placebo; Drug
Lead sponsor: Jason Stubbs, MD; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Kidney Stone, Normal Controls
Interventions: Kidney stones Normal controls Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic; Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infection
Interventions: FTC/TDF (Truvada®); Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 15 Years to 22 Years · Male only
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more

Conditions: Kidney Cancer
Interventions: recombinant interferon alfa, tretinoin liposome; Biological · Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 2
States / cities: New York, New York

Conditions: Renal Failure
Interventions: BMS-986259; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Saint Paul, Minnesota

Conditions: Pulmonary Arterial Hypertension, Renal Dysfunction
Interventions: UT-15C SR (treprostinil diethanolamine); Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Renal Calculus, Kidney Stones
Interventions: Ketorolac, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Anemia
Interventions: Epoetin Alfa; Drug
Lead sponsor: Mehrotra, Anita, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Exercise Trial in Chronic Kidney Disease

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria

A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally

Glucocorticoid-induced Osteopenia in Children

A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

Amnioinfusion for Fetal Renal Failure

A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

Community-Associated Uropathogen Antimicrobial Resistance Among Emergency Department Patients With Acute Pyelonephritis

Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer

Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines

Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab

Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

NeoVax Plus Ipilimumab in Renal Cell Carcinoma

Virtually Supervised Exercise for Kidney Transplant Candidates

Rifaximin Therapy in Chronic Kidney Disease

Oxalate and Citrate

Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM).

Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer

A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function

The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil

Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy

Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation